Chronic lymphocytic leukemia patients with high-risk genomic features have inferior outcome on successive CALGB trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101

Alemtuzumab consolidation has been investigated to improve remission duration after fludarabine-based induction for chronic lymphocytic leukemia (CLL). The impact on genomic high-risk disease remains unknown. CALGB 19901 and 10101 enrolled previously untreated patients to receive alemtuzumab consoli...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Jones, Jeffrey A., Ruppert, Amy S., Zhao, Weiqiang, Lin, Thomas S., Rai, Kanti, Peterson, Bercedis, Larson, Richard A., Marcucci, Guido, Heerema, Nyla A., Byrd, John C.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3766417/
https://ncbi.nlm.nih.gov/pubmed/23547837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2013.788179
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky